Source

Article date: 2026-04-16 (CNBC, Brandon Gomez). Captured 2026-05-05 PT during peptide-economy watchlist build-out.

The news: HHS Secretary RFK Jr. announced 2026-04-15 that the FDA will convene a Pharmacy Compounding Advisory Committee in July 2026 to review peptides for inclusion on the 503A bulk list — the designation that allows drugs to be compounded on individual prescription rather than mass-produced.

Why HIMS specifically: HIMS acquired a California peptide facility in February 2025 — pre-dating the policy news by ~14 months. CEO Andrew Dudum called peptide demand "future-facing innovation" at the time. Now the regulatory path validates the bet. CMO Dr. Patrick Carroll framed the news as a move "away from the gray market" into "regulated, physician-led care."

Sell-side reaction: Leerink (Michael Cherny) — peptide bulk-list inclusion is "a clearer regulatory path to scale peptide therapies." But: "would not immediately translate into revenue, but would seemingly be a growth avenue HIMS would push hard on." Hold-equiv rating, $25 PT vs ~$26 trading.

Specific peptides under review (12 listed by Kennedy):

• MK-677 — growth hormone, often treated as illegal when sold for human consumption, banned by World Anti-Doping Agency (the controversial one).
• GHK-Cu — cosmetic peptide.
• Semax — cognitive enhancement.
• Others: not yet enumerated in the article. Clinical evidence...